Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Leqvio Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Leqvio (inclisiran) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Advantage Part B prior authorization and coverage criteria for Leqvio in adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional LDL-C lowering.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyLeqvio (inclisiran) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit the patient's most recent LDL-C level and medical records supporting the request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered adult populations
    1 yearInitial coverage
    2 yearsReauthorization
    RequiredSpecialist prescriber
    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prohibited therapies
    1 mgBilling unit

    Coverage Criteria

    Initial Therapy Criteria

    Covered when all of the following are met:

    Eligible initial therapy

    • Covered disease indication

      • The patient has heterozygous familial hypercholesterolemia (HeFH).
      • The patient has clinical atherosclerotic cardiovascular disease (ASCVD).

    Continuation Therapy Criteria

    Reauthorization is available for two years when the following criterion is met:

    Continuation dosing: Continued dosing must be consistent with FDA-approved labeling or accepted standards of medical practice.

    Reauthorization coverage is for two years.

    Leqvio must not be used in combination with a PCSK9 inhibitor (for example, Repatha), Nexletol, or Nexlizet.

    Provider Actions and Requirements

    Documentation Required

    Eligible Indication and Treatment Context

    Document that the adult has heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring additional lowering of low-density lipoprotein cholesterol (LDL-C). Leqvio must be used as an adjunct to diet and maximally tolerated statin therapy.

    Prior Authorization

    Specialist Prescriber and Clinical Documentation

    The request must identify a qualified specialist prescriber or document consultation with one, and include the clinical rationale for Leqvio therapy and the need for additional LDL-C lowering.

    • Prescriber must be a cardiologist, endocrinologist, or board-certified lipidologist, or the request must document consultation with one.
    Documentation Required

    Clinical Background

    Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy directed to PCSK9 messenger RNA. It is used as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

    Key Terms

    Definition
    TermHeFH
    DefinitionHeterozygous familial hypercholesterolemia
    Policy relevanceAn eligible adult indication for Leqvio when additional LDL-C lowering is required
    Definition
    TermASCVD
    DefinitionAtherosclerotic cardiovascular disease
    Policy relevanceAn eligible adult indication for Leqvio when additional LDL-C lowering is required

    Initial Therapy

    Initial Therapy Criteria

    Initial coverage is for one year and requires all of the following:

    Initial Leqvio eligibility: The patient is an adult with an eligible indication and requires additional LDL-C lowering while receiving diet therapy and maximally tolerated statin therapy.

    Eligible indications are heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD).

    Reauthorization and Continuation

    Reauthorization Criteria

    Reauthorization coverage is for two years when the following criterion is met:

    Continuation dosing: Dose is approved according to FDA-approved labeling or within accepted standards of medical practice.

    Reauthorization coverage is for two years.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyLeqvio (inclisiran) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit the patient's most recent LDL-C level and medical records supporting the request.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and RequirementsClinical BackgroundKey TermsInitial TherapyReauthorization and Continuation

    Required Medical Documentation

    Submit the most recent LDL-C level with the request. Medical records supporting the request must also be provided.

    • Most recent LDL-C result
    • Supporting medical records

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Definition
    TermLDL-C
    DefinitionLow-density lipoprotein cholesterol
    Policy relevanceThe request must include the patient's most recent LDL-C level; Leqvio is used when additional lowering is required
    Definition
    TermPCSK9
    DefinitionProprotein convertase subtilisin kexin type 9
    Policy relevanceLeqvio is directed to PCSK9 messenger RNA and must not be used in combination with a PCSK9 inhibitor
    Definition
    TermsiRNA
    DefinitionSmall interfering RNA
    Policy relevanceLeqvio is a small interfering RNA therapy directed to PCSK9 messenger RNA